Does growth hormone supplementation improve oocyte competence and IVF outcomes in patients with poor embryonic development? A randomized controlled trial.

Plain-language guide to PMID 32434490 (2020): randomized controlled trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 158 patients.

Key Facts

PMID: 32434490
Journal: BMC pregnancy and childbirth
Year: 2020
Study type: Randomized Controlled Trial
Authors: Li J et al. (5 authors)
DOI: 10.1186/s12884-020-03004-9

What This Study Did, in Plain Language

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

ChiCTR1900021992 posted March 19, 2019 (retrospectively registered).

Who Took Part

The study group was 158 patients.

The age groups tagged for this paper are adults, women only.

A randomized controlled trial including 158 patients with poor embryo development was conducted between July 2017 and February 2019.

One hundred and seven patients were randomized for GH treatment (GH group) and 51 patients for untreated (control group).

How the Study Was Run

The design is described as randomized.

Because people in this Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The primary end-points were the clinical pregnancy and live birth rates in the two groups.

The oocyte competence were assessed through calculating the mitochondrial DNA (mtDNA) copy number in corresponding cumulus granulosa cells (CGCs).

Quantitative PCR were used for calculation of mtDNA copy number.

What Was Measured

Topics PubMed links to this paper include Birth Rate, China, Embryo Implantation, Embryo Transfer, Embryonic Development, Fertilization in Vitro and Growth Hormone.

Author keywords: In vitro fertilization, Mitochondrial DNA, Oocyte competence and Poor embryonic development.

What This Means in Plain Language

The paper is a randomized study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 158 patients.

Its findings take up roughly 5 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2020 (BMC pregnancy and childbirth), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.